Why S.F. biotech's clinical trial may add to new dash for fatty liver disease NASH

A mid-stage clinical trial points the company toward a Phase III study in patients with nonalcoholic steatohepatitis, or NASH, and sent the stock soaring Wednesday.

Source: bizjournals.com Health Care:Physician Practices headlines - March 22, 2023 Category: American Health Authors: Ron Leuty Source Type: news